704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster I

Trial in progress A Phase 2a Study of GI 102 CD80 IL2v3 as a consolidation therapy in patients with relapsed refractory diffuse large B cell lymphoma following anti CD19 chimeric antigen receptor T cell therapy CARNATION trial

Inotuzumab ozogamicin vs blinatumomab bridging optimization and second CD19 CAR T efficacy in Relapsed Refractory B ALL

Real time interleukin 6 IL 6 kinetics predict cytokine release syndrome CRS in patients receiving chimeric antigen receptor CAR T cell therapy for Relapsed Refractory B cell malignancies

IL18 armored CAR T cells in patients with CLL SLL and Richter s transformation after prior BTK inhibitor and venetoclax failure

Clinical burden and predictors of cytokine release syndrome in CAR T cell therapy for hematologic malignancies Insights from a national cohort

Ruxolitinib for refractory immune effector cell enterocolitis following ciltacabtagene autoleucel CAR T cell therapy for multiple myeloma

TSC 101 eliminates recipient hematopoietic cells and demonstrates potential for improved relapse free survival in patients with AML ALL or MDS undergoing allogeneic HCT Updated results from the Phase 1 ALLOHA trial

Fraternal but not identical twins HLH and ICANS look a lot alike

Parkinsonism and other non immune effector cell associated neurotoxicities related to BCMA directed chimeric antigen receptor T cell therapy

Safety tolerability and early efficacy of mdc CAR BCMA001 – a high affinity BCMA targeting CAR T cell therapy in patients with multiple myeloma and diffuse large B cell lymphoma

OL 101 a BCMA GPRC5D dual targeting autologous CAR T for relapsed refractory multiple myeloma R R MM Results from a Phase I study

Direct IL 6 sequestration with siltuximab rescues CAR T cell proliferation from inflammatory suppression A longitudinal multi omic analysis supporting a paradigm shift in CRS management

Safety and immunomodulatory effects of siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T cell CD19 CART therapy for B cell lymphomas Final phase I trial results

One year follow up of CD19 BCMA dual targeting fastcar T GC012F AZD0120 therapy in patients with refractory systemic lupus erythematosus

Glofitamab use may significantly reduce the efficacy of CAR T therapy in R R DLBCL patients

Immune remodeling enables sustained EBV clearance in B cell and plasma cell malignancies after anti CD19 BCMA CAR T therapy A post hoc analysis

BCMA targeted CAR T cell therapy in refractory autoimmune diseases Initial Results from a Phase 1 clinical trial

The ratio of post infusion circulating PD 1 CAR T subsets to product PD 1 CAR T cells serves as a predictive biomarker for long term disease control in CAR T cell therapy for R R B cell lymphoma

Long term follow up of nivolumab ipilimumab primed immunotransplant in patients with Relapsed Refractory DLBCL

Optimizing fludarabine exposure using pharmacokinetic modeling in pediatric patients receiving tisagenlecleucel A step toward personalized lymphodepletion

Pre CAR T pulmonary function test and respiratory comorbidities have limited predictive value for survival toxicities and respiratory complications

Safety and preliminary efficacy of combined lenalidomide and CD19 CAR T cell therapy in relapsed refractory CLL A phase I study

Safety and preliminary efficacy of a novel loop optimized BCMA CD19 bispecific CAR T therapy for refractory or relapsed autoimmune diseases patients

INO transit Inotuzumab ozogamicin treatment prior to chimeric antigen receptor T cell therapy in Relapsed Refractory B cell acute lymphoblastic leukemia Real world patient characteristics and outcomes in Spain the UK and US

CD7 chimeric antigen receptor T cells for relapsed refractory T cell lymphomas Single arm open label phase I study

Evaluation of commercially available chimeric antigen receptor CAR detection reagents for monitoring of CAR T cell CAR T expansion and persistence in patients pts treated with obecabtagene autoleucel obe cel

Pre existing clonal hematopoiesis in CAR T recipients is not associated with increased immunotoxicity and inflammatory serum signatures

ST2 as a biomarker of cytokine release syndrome following CD19 targeted chimeric antigen receptor T cell therapy

Renal and urinary adverse events following CAR t therapy A faers based pharmacovigilance analysis